PatchO Patchouli Oil (Pogostemon cablin)
Description: <p><b>Patchouli Oil (Pogostemon cablin)</b> — Patchouli oil is a volatile botanical essential oil obtained primarily by distillation of Pogostemon cablin leaves. It is a chemically variable mixture of sesquiterpenes, including patchouli alcohol, also called patchoulol, and other constituents whose proportions depend on plant material and processing. The oil is used commercially in fragrances and traditional preparations and is being investigated as a preclinical anticancer agent. Whole oil, nonvolatile plant extracts, and purified PA are distinct experimental materials.</p>
<p><b>Primary mechanisms (ranked):</b></p>
<ol>
<li>OR13G1–CaMKK2–AMPK signaling and ferroptosis: whole patchouli oil and PA increased OR13G1 expression, activated CaMKK2/AMPK signaling, and promoted ferroptotic cancer-cell death in colorectal cancer models.</li>
<li>Mitochondrial apoptosis and cell-cycle arrest: purified PA reduced mitochondrial membrane potential, activated caspase-dependent apoptosis, and inhibited cell-cycle progression in several cancer models. These findings cannot automatically be assigned to every whole-oil preparation.</li>
<li>Suppression of survival signaling: PA inhibited NF-κB–MCL-1 signaling in castration-resistant prostate cancer models and altered EGFR/MAPK signaling in lung cancer models.</li>
<li>Autophagic cell death: a mechanistic study identified GNAI1 as a PA target and reported disruption of the GNAI1–ARRB1 complex, suppression of ERK/JAK2–STAT3/mTOR signaling, and autophagic death in non-small-cell lung cancer models.</li>
<li>Oxidative DNA damage: PA increased ROS and DNA-damage responses in parental and vincristine-resistant lung cancer cells. This is model-dependent and should not be generalized to normal tissues.</li>
<li>Epigenetic and proliferation effects: PA reduced HDAC activity, HDAC2 expression, and c-MYC expression in colorectal cancer cells.</li>
<li>Secondary invasion and combination effects: PA reduced migration-associated proteins in selected models and enhanced cisplatin effects in experimental melanoma systems.</li>
</ol>
<p><b>Bioavailability / PK relevance:</b> Patchouli oil is hydrophobic, and systemic exposure depends on composition, formulation, and administration route. Rat studies demonstrate absorption of PA after oral administration of either PA or whole oil, but these preparations have different pharmacokinetic profiles. Human anticancer pharmacokinetics, effective exposure, and a therapeutic dosing schedule have not been established. Aromatherapy or cosmetic exposure cannot be assumed to reproduce experimental tumor exposure.</p>
<p><b>In-vitro vs systemic exposure relevance:</b> PA experiments commonly use concentrations in the tens to hundreds of micromolar range; examples include approximately 112–135 µM in lung cancer experiments and 50–100 µg/mL, approximately 225–450 µM, in other studies. These concentrations are not established as safely achievable in human tumors. Without human exposure data, the gap cannot be quantified reliably. Whole-oil concentrations must be reported separately from PA concentrations.</p>
<p><b>Clinical evidence status:</b> Preclinical cancer evidence includes cell experiments and mouse studies. No convincing human anticancer efficacy evidence or established oncology indication was identified. Commercial fragrance use and traditional use do not establish cancer efficacy or the safety of concentrated oral dosing. No evidence-based oral anticancer dose can be recommended.</p>
<h3>Patchouli oil and constituent mechanisms</h3>
<table>
<thead>
<tr>
<th>Rank</th>
<th>Pathway / Axis</th>
<th>Cancer Cells</th>
<th>Normal Cells</th>
<th>Primary Effect</th>
<th>Notes / Interpretation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>OR13G1–CaMKK2–AMPK and ferroptosis</td>
<td>↑ OR13G1 expression; ↑ CaMKK2/AMPK signaling; ↑ ferroptosis</td>
<td>Tumor-bearing mice showed reduced colonic inflammation and pathological injury; normal-cell selectivity remains incompletely established</td>
<td>Suppression of colorectal tumor development and cancer-cell growth</td>
<td>Direct evidence for both whole oil and PA in a 2026 study using colorectal cancer cells and an inflammation-associated mouse cancer model. Independent replication is needed.</td>
</tr>
<tr>
<td>2</td>
<td>Mitochondrial apoptosis and cell-cycle control</td>
<td>↓ Mitochondrial membrane potential; ↑ caspase activation; ↑ cell-cycle arrest</td>
<td>Some studies included nonmalignant comparator cells; a human therapeutic window is unestablished</td>
<td>Apoptotic death and reduced proliferation</td>
<td>Predominantly PA evidence. Mitochondrial depolarization does not by itself establish mitochondrial permeability transition pore opening.</td>
</tr>
<tr>
<td>3</td>
<td>NF-κB–MCL-1 survival signaling</td>
<td>↓ NF-κB activation; ↓ MCL-1; ↑ apoptosis</td>
<td>Comparable modulation and safety at anticancer exposure are unestablished</td>
<td>Reduced antiapoptotic signaling</td>
<td>PA evidence from DU145 and PC-3 prostate cancer cells and mouse xenografts. MCL-1 overexpression partly reversed the apoptotic effect.</td>
</tr>
<tr>
<td>4</td>
<td>GNAI1–ARRB1 and autophagic cell death</td>
<td>↓ GNAI1–ARRB1 interaction; ↓ ERK/JAK2–STAT3/mTOR signaling; ↑ autophagic death</td>
<td>Effects on normal tissues require further characterization</td>
<td>Disruption of survival signaling and induction of lethal autophagy</td>
<td>Mechanistic PA evidence in non-small-cell lung cancer. Autophagy can support survival in other settings; this is not a universal direction of effect.</td>
</tr>
<tr>
<td>5</td>
<td>EGFR and MAPK signaling</td>
<td>↓ EGFR-associated signaling; altered MAPK activity; ↑ apoptosis and cell-cycle arrest</td>
<td>Insufficient evidence for a consistent normal-cell response</td>
<td>Reduced growth signaling</td>
<td>PA evidence in A549 lung cancer models. Individual MAPK branches should be recorded separately rather than assigning one direction to all MAPK signaling.</td>
</tr>
<tr>
<td>6</td>
<td>ROS-mediated DNA damage</td>
<td>↑ ROS; ↑ DNA-damage response; ↑ apoptosis</td>
<td>No established selective pro-oxidant effect across normal tissues</td>
<td>Oxidative stress-associated growth inhibition</td>
<td>PA evidence in parental and vincristine-resistant lung cancer cells. This mechanism is distinct from the whole-oil ferroptosis finding.</td>
</tr>
<tr>
<td>7</td>
<td>HDAC2 and c-MYC</td>
<td>↓ HDAC activity; ↓ HDAC2 expression; ↓ c-MYC</td>
<td>Normal-cell epigenetic effects are insufficiently characterized</td>
<td>Reduced proliferation and altered cell-cycle regulation</td>
<td>PA evidence in colorectal cancer cells. Reduced enzyme activity and expression do not establish selective direct binding to HDAC2.</td>
</tr>
<tr>
<td>8</td>
<td>Migration and invasion</td>
<td>↓ Migration and invasion; ↓ selected MMPs; ↑ E-cadherin in melanoma models</td>
<td>Effects on normal migration and wound repair cannot be inferred from tumor assays</td>
<td>Reduced invasive phenotype</td>
<td>Mostly PA evidence. Cell migration assays do not establish prevention of metastasis in patients.</td>
</tr>
<tr>
<td>9</td>
<td>Cisplatin combination</td>
<td>↑ Combination inhibition of colony formation and migration in melanoma experiments</td>
<td>Human combination toxicity and pharmacokinetic interactions are unknown</td>
<td>Experimental chemosensitization</td>
<td>PA evidence from B16F10 melanoma research. No clinical combination regimen is established; whole oil should not be assumed equivalent.</td>
</tr>
<tr>
<td>10</td>
<td>Clinical Translation Constraint</td>
<td>Experimental activity depends on preparation, concentration, and tumor model</td>
<td>Systemic safety at proposed anticancer exposures is unestablished</td>
<td>Limits clinical interpretation</td>
<td>Variable oil composition, formulation-dependent absorption, high experimental concentrations, limited selectivity data, and absence of human anticancer trials prevent assignment of a therapeutic dose.</td>
</tr>
</tbody>
</table>